Moderna posts Phase 2 mRNA-1083 results; VX-522 completes; new Phase 3b/4 study registers

- A Phase 2 study evaluated the safety, reactogenicity, and immunogenicity of mRNA-1083, a combined SARS-CoV-2 and influenza vaccine, given as a single intramuscular injection to adults 50 to under 65 years old.

A Phase 2 study evaluated the safety, reactogenicity, and immunogenicity of mRNA-1083, a combined SARS-CoV-2 and influenza vaccine, given as a single intramuscular injection to adults 50 to under 65 years old.¹ The study is listed as completed, with results first posted October 8, 2026, and it enrolled 931 participants¹, measuring geometric mean titer of anti-hemagglutinin antibody for seasonal influenza A and B strains at Day 29¹ and geometric mean titer of neutralizing antibody for SARS-CoV-2 at Day 29¹.
A Phase 1/2 dose-escalation study tested VX-522, an mRNA therapy, in adults with cystic fibrosis whose CFTR genotype does not respond to CFTR modulator therapy, sponsored by Vertex Pharmaceuticals with Moderna, Inc as collaborator.² The study is listed as completed, enrolling 26 participants² across 26 sites in seven countries including the United States, Australia, Belgium, Canada, Germany, Sweden, and the United Kingdom².
ModernaTX registered an open-label Phase 3b/4 study to evaluate the immunogenicity and safety of variant-formulation mRNA-1273 and mRNA-1283 vaccines, with an estimated enrollment of 300 participants and a planned start of October 9, 2026.³ The record is listed as not yet recruiting, and eligible participants must be 65 or older, or 12 to under 65 with at least one risk factor for severe COVID-19 outcomes³.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.